Japan’s Sawai Benefits In Domestic Market From Rivals’ Supply Misery
As Analyst Urges Sawai To Up Domestic Production Capacity
Sawai was strong in Japan and weak in the US in the first financial quarter of its 2022 financial year, as analysts called on the Japanese firm to improve supply capacity as a “crucial first step towards expanding market share.”
You may also be interested in...
Nichi-Iko has been forced to cut dramatically its core operating profit guidance for its 2022 financial year, as it continues to deal with the fallout of its previously deficient Namerikawa manufacturing facility in the Toyama prefecture.
Sawai is lining up eight launches as part of the Japanese company’s strategy to capture an increased share of its domestic generics market.
Glenmark said it would continue to deliver new respiratory products in Europe moving forward as the Indian firm lines up what it believes will be the first generic version of Boehringer Ingelheim’s Spiriva Handihaler.